Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...

Reports collaboration and license revenue related to the Kyorin Agreement was $200K for the year ended 2024, which consisted of drug product ...

SAN DIEGO - aTyr Pharma, Inc. (NASDAQ: ATYR) reported a narrower-than-expected fourth quarter loss on Wednesday, but shares fell 4.8% in after-hours trading as investors focused on the company’s cash ...

The FDA approved a prefilled syringe format for Ani's purified Cortrophin Gel that should ease administration for MS patients ...

Peer-reviewed publication validates efzofitimod’s unique anti-inflammatory mechanism of action on macrophages through ...

SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), on Friday announced that the independent Data and Safety Monitoring Board or DSMB has completed a fourth pre-planned interim safety analysis for the ongoing ...

Staying passionate about it is easy. Her goal is to celebrate the rich heritage of Mexican cuisine — without compromising her ...

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

Close to 300 women wore red as a sign of solidarity and determination at the Go Red for Women luncheon at the DoubleTree by Hilton in Bakersfield on Friday. For two decades the American Heart ...

The McCormick Foundation Center Forum seats were filled with over 50 Northwestern students, faculty and staff members for a panel titled “The University Under Threat” on Thursday night. “It was ...

My residency director, David Carey, used to say ironically, “If you step back and take a careful look, you’ll see there’s a ...